Investor Presentaiton
Financial Highlights - Profit and Loss Statement
Particulars (cr.)
9MFY22
9MFY21
YOY
Q3FY22
Q2FY22
Q3FY21
YOY
Operating Revenue
1,072.8
1,046.0
2.6%
362.6
361.2
358.5
1.2%
Gross Profit
567.6
601.1
(5.6)%
195.1
185.8
216.9
(10.1)%
Gross Profit Margin %
52.9%
57.5%
(460) Bps
53.8%
51.4%
60.5%
(670) Bps
EBITDA
195.2
244.2
(20.1)%
57.8
60.1
91.1
(36.5)%
EBITDA Margin %
18.2%
23.3%
(510) bps
15.9%
16.6%
25.4%
(950) bps
Finance Costs
3.4
5.2
(33.7)%
1.0
1.5
1.7
(43.2)%
Depreciation & Amortization*
23.4
34.8
(32.7)%
8.6
7.4
8.6
(0.2)%
Other Income
26.5
0.7
3,781.3%
12.1
8.6
(3.2)
NA
Profit before tax
194.9
204.9
(4.9)%
60.4
59.8
77.6
(22.3)%
Taxes
37.8
45.9
(17.8)%
12.1
13.5
18.7
(35.4)%
Net Profit
157.2
159.1
(1.2)%
48.3
46.3
58.9
(18.1)%
Net Profit Margin %
14.3%
15.2%
(90) Bps
12.9%
12.5%
16.6%
(370) Bps
Diluted EPS (*)
3.82
3.83
(0.3)%
1.20
1.11
1.42
(15.7)%
*Includes accelerated depreciation of 10.0 cr. in 9MFY21
©2021 - Marksans Pharma Limited, All Rights Reserved.
6View entire presentation